GlobeNewswire Inc | Sep 8, 2020 04:01PM EDT

September 08, 2020

TUCSON, Ariz., Sept. 08, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced JohnLubniewski, President and CEO of HTG, will present virtually at the H.C. Wainwright 22ndAnnual Global Investment Conference and at the Cantor Fitzgerald Global Healthcare Conference. Details are as follows:

H.C. Wainwright 22^nd Annual Global Investment ConferenceDate: Tuesday, September 15^thTime: 3:00 pm Eastern TimeWebcast: No Webcast Cantor Fitzgerald Global Healthcare ConferenceDate: Wednesday, September 16^thTime: 10:00 am Eastern TimeWebcast: Click here for link

About HTG

HTG is focused on NGS-based molecular profiling. The companys proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTGs customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.

Contact: Ashley R. Robinson LifeSci Advisors, LLC Phone: (617) 430-7577 Email:arr@lifesciadvisors.com